欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (4): 433-439.doi: 10.12092/j.issn.1009-2501.2019.04.011

• 药物治疗学 • 上一篇    下一篇

抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究

张腾跃1,杨广山2,马克龙3,范平生1   

  1. 安徽省肿瘤医院,中国科学技术大学附属第一医院,中国科学技术大学生命科学与医学部,1肿瘤内科,2中医科,合肥 230000,安徽; 3安徽中医药大学中西医结合临床学院,生物化学教研室,合肥 230000,安徽
  • 收稿日期:2018-11-22 修回日期:2019-03-20 出版日期:2019-04-26 发布日期:2019-05-01
  • 通讯作者: 范平生,男,本科,主任医师,博士生导师,研究方向:肝素抗肿瘤转移的基础与临床研究。 Tel:13956010593 E-mail:fanpingsheng@csco.ac.cn
  • 作者简介:张腾跃,男,博士,主治医师,研究方向:肝素抗肿瘤转移的基础与临床研究。 Tel:13855188692 E-mail:zhty6580@sina.com
  • 基金资助:

    安徽省自然科学基金面上项目(1408085QH182);中国科学技术大学“科大新医学”培育基金(WK9110000024)

Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer

ZHANG Tengyue 1, YANG Guangshan 2, MA Kelong 3, FAN Pingsheng 1   

  1. 1 Department of Oncology, 2 Department of Chinese Medicine, Anhui Provincial Cancer Hospital, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui, China; 3 Biochemistry Department, Integrated Traditional Chinese and Western Medicine College, Anhui University of Traditional Chinese Medicine, Hefei 230000, Anhui, China
  • Received:2018-11-22 Revised:2019-03-20 Online:2019-04-26 Published:2019-05-01

摘要:

目的:分析胃癌患者凝血指标与临床病理特征的关系,观察抗凝治疗对高凝状态、肿瘤转移、生存期的影响及安全性评价。方法:选取140例胃癌患者,分析凝血指标与临床病理特征的关系。选取III期胃癌患者172例,分为治疗组(抗凝治疗联合化疗)116例,对照组56例(单用化疗),观察抗凝治疗对高凝状态、肿瘤转移、生存期的影响及安全性评价。结果:淋巴结转移N1-3组较N0组D-二聚体升高(P<0.05),III、IV期较I、II期血浆纤维蛋白原(FIB)、D-二聚体升高,部分活化凝血活酶时间(APTT)数值降低(P<0.05)。治疗组抗凝治疗后,血浆凝血酶原时间(PT)、APTT延长,D-二聚体、FIB降低(P<0.05)。治疗组的12月、24月、36月腹腔淋巴结、肝脏转移率较对照组降低(P<0.05)。治疗组2年、3年生存率高于对照组(P<0.05),中位生存期及无病生存期较对照组延长。两组牙龈出血、血小板减少、皮肤瘀点瘀斑发生率无统计学差异(P>0.05)。结论:胃癌高凝状态影响因素为淋巴结转移、TNM分期偏晚。抗凝治疗可改善高凝状态,降低腹腔淋巴结及肝脏转移率,延长生存期,未增加上述不良反应发生率。

关键词: 抗凝治疗, 胃癌, 高凝状态, 转移, 生存期

Abstract:

AIM: To analyze the relationship between coagulation parameters and clinic pathological features of gastric cancer patients, and observe the effect of anticoagulant therapy on hypercoagulable state, tumor metastasis/recurrence, survival status and safety evaluation of gastric cancer. METHODS: 140 patients with gastric cancer were selected to analyze the relationship between coagulation parameters and clinic pathological features. 172 patients with stage III gastric cancer were enrolled, including 116 patients in the treatment group (prophylactic anticoagulant therapy combined with postoperative adjuvant chemotherapy) and 56 patients in the control group (postoperative adjuvant chemotherapy). The anticoagulant therapy was observed on hypercoagulable state and tumor metastasis/recurrence, impact of survival and safety assessment. RESULTS:D-dimer of lymph node metastasis N1-3 group was higher than N0 group (P<0.05), stage III and IV were higher than stage I and II of FIB, D-dimer, and APTT value was decreased (P<0.05). Before and after anticoagulant therapy in the treatment group, PT and APTT were prolonged, D-dimer and FIB were decreased (P<0.05). The rate of lymph node and liver metastasis in the treatment group was lower than that in the control group in 12, 24 and 36 months (P<0.05). The 2-year and 3-year survival rates of the treatment group were higher than those of the control group (P<0.05), and the median survival and disease-free survival were longer than the control group. There was no significant difference in the incidence of gingival bleeding, thrombocytopenia, and ecchymosis of the skin between the two groups (P>0.05). CONCLUSION:The factors influencing the hypercoagulable state of gastric cancer are lymph node metastasis and TNM staging. Anticoagulant therapy can improve hypercoagulability, reduce the rate of lymph node and liver metastasis, and prolong survival without increasing the incidence of adverse reactions.

Key words: anticoagulant therapy, gastric cancer, hypercoagulable state, metastasis, survival analysis

中图分类号: